<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918459</url>
  </required_header>
  <id_info>
    <org_study_id>2021.221</org_study_id>
    <nct_id>NCT04918459</nct_id>
  </id_info>
  <brief_title>EUS Guided Cyanoacrylate Injection vs Endoscopic Variceal Band Ligation for Prevention of Rebleeding in Patients With Hepatocellular Carcinoma and Esophageal Variceal Bleeding</brief_title>
  <acronym>EUSgluevsVBL</acronym>
  <official_title>EUS Guided Cyanoacrylate Injection vs Endoscopic Variceal Band Ligation for Prevention of Rebleeding in Patients With Hepatocellular Carcinoma and Esophageal Variceal Bleeding: a Retrospective Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SP by EUS-CYA improves clinical outcomes (eg, EV rebleeding) in patients with HCC and prior&#xD;
      EV bleeding when compared with SP by EGD-VBL&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Variceal bleeding is a life-threatening complication in patients with portal hypertension and&#xD;
      cirrhosis. Rebleeding is common in patients who survive the acute variceal bleeding episode&#xD;
      without secondary prophylaxis (SP). Hepatocellular carcinoma (HCC) and portal vein thrombosis&#xD;
      (PVT) are associated with recurrent variceal bleeding and worse clinical outcomes. Rebleeding&#xD;
      rates of esophageal varices (EV) and gastric varices (GV) remain substantial in HCC patients&#xD;
      despite conventional endoscopic treatments.&#xD;
&#xD;
      Lack of SP was associated with a higher rate of rebleeding and mortality in a multicenter&#xD;
      study of HCC patients with prior EV bleeding. SP of variceal rebleeding in suitable HCC&#xD;
      patients has been suggested in the latest practice guideline of the American Association for&#xD;
      the Study of Liver Diseases, but the optimal endoscopic approach for SP in HCC patients has&#xD;
      not been well defined. Whether conventional strategies such as variceal band ligation (VBL)&#xD;
      or cyanoacrylate (CYA) injection for EV can achieve durable variceal control in HCC patients&#xD;
      remains unclear since HCC patients were often excluded from clinical trials. This remains a&#xD;
      pertinent issue as recent advances in the treatment of advanced HCC with tyrosine kinase&#xD;
      inhibitors (TKI) and immunotherapy means that some patients may achieve reasonable survival&#xD;
      and benefit from further variceal management.&#xD;
&#xD;
      Recently, endoscopic ultrasound (EUS) guided variceal interventions by CYA, coiling, or a&#xD;
      combination of both have gained clinical attention due to its high clinical success. When&#xD;
      compared with conventional endoscopic variceal treatments, EUS guided variceal interventions&#xD;
      allow real-time confirmation of intra-variceal delivery of therapy and flow obliteration&#xD;
      after treatment. A recent study from our group reported that SP by EUS-CYA reduced rebleeding&#xD;
      rate and improved variceal bleeding-free survival in patients with inoperable HCC and&#xD;
      variceal bleeding when compared with no SP. However, there has been no dedicated study&#xD;
      comparing the clinical outcomes of SP by EUS guided CYA (EUS-CYA) or conventional VBL by&#xD;
      esophagogastroduodenoscopy (EGD) in patients with HCC and EV bleeding. Therefore, we propose&#xD;
      this retrospective study to compare the clinical outcomes after EUS-CYA or EGD-VBL for SP of&#xD;
      EV rebleeding in this often difficult-to-treat patient group with HCC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 6, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Death adjusted cumulative incidence of rebleeding at 30-day</measure>
    <time_frame>30 days</time_frame>
    <description>Death adjusted cumulative incidence of rebleeding at 30-day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death adjusted cumulative incidence of rebleeding at 90-day</measure>
    <time_frame>90 days</time_frame>
    <description>Death adjusted cumulative incidence of rebleeding at 90-day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding-free survival at 3 months and 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Bleeding-free survival at 3 months and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events related to EUS-CYA or EGD-VBL for secondary prophylaxis</measure>
    <time_frame>during EUS procedure</time_frame>
    <description>Adverse events related to EUS-CYA or EGD-VBL for secondary prophylaxis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Mortality rate at 6 months</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>EUS Guided Cyanoacrylate Injection</condition>
  <condition>Endoscopic Variceal Band Ligation</condition>
  <condition>Hepatocelular Carcinoma</condition>
  <condition>Esophageal Variceal Bleeding</condition>
  <arm_group>
    <arm_group_label>EUS guided cyanoacrylate injection</arm_group_label>
    <description>EUS guided cyanoacrylate injection to prevent EV rebleeding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>variceal band ligation</arm_group_label>
    <description>variceal band ligation to prevent EV rebleeding.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        HCC apatients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Consecutive HCC patients with history of EV bleeding who underwent EUS guided&#xD;
             cyanoacrylate injection or variceal band ligation by EGD for secondary prophylaxis to&#xD;
             prevent EV rebleeding&#xD;
&#xD;
          2. Age &gt; 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HCC patients with non-variceal upper GI bleeding&#xD;
&#xD;
          2. HCC patients with history of EV bleeding who did not undergo further endoscopy for&#xD;
             secondary prophylaxis for EV rebleeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Felix Sia</last_name>
    <phone>26370428</phone>
    <email>felixsia@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Lam</last_name>
    <phone>26370428</phone>
    <email>thomaslam@cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prince of Wales Hospital, The Chinese University of Hong Kong</name>
      <address>
        <city>Sha Tin</city>
        <state>New Territories</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Lam, BS</last_name>
      <phone>852-3505-3509</phone>
      <email>thomaslam@cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>Raymond S Tang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Raymond Shing Yan Tang</investigator_full_name>
    <investigator_title>Assitant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

